LON:IMM

ImmuPharma Interim Earnings Results & Report

ImmuPharma logo
GBX 2.90 +0.49 (+20.37%)
As of 11:58 AM Eastern

ImmuPharma reported Interim earnings on September 15, 2026. The company reported EPS of -GBX 0.84.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

ImmuPharma EPS Results

Actual EPS
-GBX 0.84
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ImmuPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

ImmuPharma Interim Earnings FAQ

ImmuPharma (LON:IMM) reported earnings of -GBX 0.84 per share for Interim. The report was announced on Tuesday, September 15, 2026.

ImmuPharma Earnings Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
See More ImmuPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email.

About ImmuPharma

ImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

View ImmuPharma Profile